X-ALD
Clinical trials for X-ALD explained in plain language.
Never miss a new study
Get alerted when new X-ALD trials appear
Sign up with your email to follow new studies for X-ALD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene therapy trial for rare nerve disease halted early
Disease control TerminatedThis study tested a one-time gene therapy called SBT101 for adults with adrenomyeloneuropathy (AMN), a rare nerve disease that affects walking. The treatment was given as a single injection into the spine. The study was terminated early after enrolling only 8 people, so results a…
Matched conditions: X-ALD
Phase: PHASE1, PHASE2 • Sponsor: SwanBio Therapeutics, Inc. • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
AMN study seeks to map Disease's slow march
Knowledge-focused TerminatedThis study was designed to track how walking ability and quality of life change over time in adults with AMN, a rare genetic nerve disease. Researchers observed 65 men aged 18 and older who had the condition but no brain inflammation. The goal was to gather data to help design fu…
Matched conditions: X-ALD
Sponsor: SwanBio Therapeutics, Inc. • Aim: Knowledge-focused
Last updated May 17, 2026 08:52 UTC